Lipella Pharmaceuticals (LIPO) announced that it has re-signed its manufacturing collaboration agreement with Cook MyoSite to support Chemistry, Manufacturing and Control, CMC, documentation supporting our clinical products LP-10 and LP-310. Dr. Jonathan Kaufman, Chief Executive Officer and Co-Founder of Lipella, said, “We are pleased to renew our collaboration with Cook MyoSite, a trusted partner with a strong track record in high-quality manufacturing. This CMC collaboration is increasingly valuable to Lipella as our clinical pipeline matures toward commercializable assets.”
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LIPO:
- Lipella Pharmaceuticals Faces Nasdaq Compliance Challenge
- Lipella Pharmaceuticals Presents Promising Phase 2a Trial Data
- Lipella Pharmaceuticals to present Phase 2a data for LP-310
- Lipella Reports Statistically Significant Results from Second Cohort in LP-310 Phase 2a Trial for Oral Lichen Planus
- Lipella abstract on LP-10 for OLP accepted for presentation at AAOM, EAOM